Q-omics provides the consensus-scored CSMD1 profile across patient tissues and cancer cell-line models. CSMD1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CSMD1 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, CSMD1 RNA expression shows 14,628 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where CSMD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSMD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSMD1 survival associations across molecular data types. CSMD1 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (10) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSMD1 RNA expression–survival associations across cancer types. High CSMD1 expression shows unfavorable associations in LIHC, but favorable associations in KIRC, HNSC, LGG, DLBC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for CSMD1 RNA expression.
This table summarizes CSMD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CSMD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSMD1 shows lower tumor expression in COAD, KICH, UCEC and KIRC and higher tumor expression in THCA and LIHC. The COAD box plot shows higher CSMD1 RNA expression in normal versus tumor tissue (log2 FC = −0.078, t-test p < 0.001).
This table shows molecular features associated with CSMD1 in patient tissues and cancer cell lines. In patient samples, CSMD1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CSMD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SKIN.
